Primary cutaneous CD4(+) small/medium‐sized T‐cell lymphoma of the face: successful treatment with radiation therapy

Topal, İlteriş Oğuz; Göncü, Emek Kocatürk; Özekinci, Selver; Ayaz, Gizem; Aksaray, Ferdi

doi:10.1111/ddg.12878

Cited by 6 publications

(10 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This clinical, histopathological, and immunophenotypic constellation, as defined in the current classification, 2 depicts a reproducibly recognized entity as reported in a number of case reports and series. 3,14–17…”

Section: Discussionmentioning

confidence: 99%

“…B cells are an almost universal finding in PCSM-LPD and can account for up to 60% of the cell population 13–19,21–26 ; these include not only small B cells but also immunoblasts that are scattered and typically surrounded by clusters of atypical CD4 + cells expressing PD-1 in a pseudorosette pattern, an observation that is a hallmark of the disease. Indeed, the follicular T-helper phenotype of the T cells is believed to be responsible for the induction of this B-cell hyperplasia.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prominent Blasts in Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorder. A Reconsideration of Diagnostic Criteria

Bakr

Wain

Wong

et al. 2021

The American Journal of Dermatopathology

View full text Add to dashboard Cite

Primary cutaneous CD4 + small/medium T-cell lymphoproliferative disorder (PCSM-LPD), recently downgraded from a T-cell lymphoma, is a poorly characterized histopathological entity. Presenting as a solitary lesion that often grows rapidly, it may raise suspicion for a cutaneous B-cell lymphoma. However, classically, the dermal lymphoid proliferation is predominantly CD4 + with a follicular T-helper profile and a smaller B-cell fraction. Diagnostic uncertainty may arise when B cells are present in large numbers, a B-cell clone is present, or large cell populations are seen. To meet the diagnostic criterion of PCSM-LPD, large cells should not constitute more than 30% of the infiltrate. The 2 cases presented in this article caused diagnostic uncertainty owing to the observation of high numbers of large cells and in one case the presence of a B-cell clone, on the background of otherwise typical clinicopathological features of PCSM-LPD. We review the literature specifically regarding the prevalence of large cell populations and their immunophenotypic characteristics and in light of this discuss whether a current diagnostic criterion should be reconsidered.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Prominent Blasts in Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorder. A Reconsideration of Diagnostic Criteria

Bakr

Wain

Wong

et al. 2021

The American Journal of Dermatopathology

View full text Add to dashboard Cite

show abstract

“…The optimal treatment for PCSMP‐TLPD has not yet been defined. However, various therapeutic options have been used for solitary lesions, including surgical excision, radiotherapy or a combination of both , as well as topical, intralesional or oral steroids , doxycycline monohydrate , amoxicillin , cryocautery and bexarotene . Systemic chemotherapy (including cyclophosphamide either as monotherapy or in association with prednisolone) , multi‐agent chemotherapy (as cyclophosphamide, hydroxydaunomycin, oncovin and prednisone (CHOP) therapy) and systemic interferon‐alfa have been used for patients with multiple aggressive lesions, which are now considered mostly as true lymphomas rather than cases of PCSMP‐TLPD.…”

Section: Discussionmentioning

confidence: 99%

Primary cutaneous CD4+ small/medium pleomorphic T‐cell lymphoproliferative disorder: Where do we stand? A systematic review

Salah

2018

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoproliferative disorder (PCSMP-TLPD) is a provisional entity with uncertain malignant potential according to the latest revision of the WHO classification for lymphoid neoplasms. We conducted a systematic literature review of all previously reported cases of PCSMP-TLPD to highlight their typical and atypical features. The main features of PCSMP-TLPD and its possible clinicopathologic overlap with similar disorders are also discussed. It is hoped that this review will provide a useful outline of this condition and the most important differential diagnoses. Finally, we recommend a rigorous consensus among cutaneous lymphoma experts in drafting diagnostic criteria and the best case definition.

show abstract

“…Eine optimale Behandlungstrategie bei PCSMP‐TLPD wurde noch nicht definiert. Bei solitären Läsionen wurden jedoch verschiedene Therapien eingesetzt, darunter chirurgische Exzision, Strahlentherapie oder eine Kombination von beidem , sowie topische, intraläsionale oder orale Steroide , Doxycyclin‐Monohydrat , Amoxicillin , Kryokauterisierung und Bexaroten . Systemische Chemotherapie (wie Cyclophosphamid als Monotherapie oder in Kombination mit Prednisolon) , Mehrfach‐Chemotherapie (wie mit Cyclophosphamid, Doxorubicin, Vincristin und Prednison [CHOP]) und systemisches Interferon‐alpha wurden bei Patienten mit mehreren aggressiven Läsionen eingesetzt, die nun überwiegend nicht mehr als Fälle von PCSMP‐TLPD, sondern als echte Lymphome betrachtet werden.…”

Section: Diskussionunclassified

Primär kutane CD4+ klein‐ bis mittelgroßzellige pleomorphe T‐Zell‐Lymphoproliferation: Wo stehen wir? Eine systematische Übersicht

Salah

2019

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Zusammenfassung Die primär kutane CD4+ klein‐ bis mittelgroßzellige pleomorphe T‐Zell‐Lymphoproliferation (PCSMP‐TLPD) ist nach der neuesten Auflage der WHO‐Klassifikation der lymphatischen Neoplasien eine vorläufige Entität mit unbekanntem malignem Potenzial. Wir führten eine systematische Literaturanalyse aller bisher publizierten Fälle von PCSMP‐TLPD durch, um ihre typischen und atypischen Merkmale herauszuarbeiten. Die wichtigsten Charakteristika der PCSMP‐TLPD und ihre mögliche klinisch‐pathologische Überlappung mit ähnlichen Erkrankungen werden ebenfalls diskutiert. Dieser Übersichts‐Artikel soll einen Überblick über diese Störung und die wichtigsten Differenzialdiagnosen bieten. Schließlich empfehlen wir, dass Experten für kutane Lymphome einen rigorosen Konsens hinsichtlich der Formulierung diagnostischer Kriterien und der besten Falldefinition finden.

show abstract

Primary cutaneous CD4(+) small/medium‐sized T‐cell lymphoma of the face: successful treatment with radiation therapy

Cited by 6 publications

References 8 publications

Prominent Blasts in Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorder. A Reconsideration of Diagnostic Criteria

Prominent Blasts in Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorder. A Reconsideration of Diagnostic Criteria

Primary cutaneous CD4+ small/medium pleomorphic T‐cell lymphoproliferative disorder: Where do we stand? A systematic review

Primär kutane CD4+ klein‐ bis mittelgroßzellige pleomorphe T‐Zell‐Lymphoproliferation: Wo stehen wir? Eine systematische Übersicht

Contact Info

Product

Resources

About